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ABSTRACT 
 
Background. Circulating tumor cells (CTC) counts of 5 or more/7.5 mL predict shorter 
survival in men with mCRPC. Moreover, the presence of androgen receptor splice variant-
7 mRNA (AR-V7) in CTCs is thought to play a relevant role in the development of primary 
or acquired resistance to enzalutamide or abiraterone.  
MiRNAs, small endogenous mRNA, have been identified as associated to the presence 
and aggressiveness of prostate cancer and for instance, overexpression of some miRNAs 
contributes to resistance to docetaxel and cabazitaxel. 
We developed a new immunofluorescence-based assay for AR-V7 expression in CTCs 
and tested its prognostic association with PFS and OS. 
Co-primary aims are to investigate AR-V7 with a new integrated assay and to study role of 
miRNAs in mCRPC patients treated with abiraterone or enzalutamide, and to study the 
relationship between AR-V7 expression, CTCs, and miRNAs with PFS or OS. 
Methods. We performed a single-centre, observational, prospective trial enrolling patients 
with mCRPC candidate to receive enzalutamide or abiraterone. CTC samples have been 
collected at baseline, after 1 month and every three months thereafter until progression or 
at 12 months without progression. CTCs have been enumerated with CellSearch System. 
We integrated the standard assay with a monoclonal antibody able to recognize the AR-V7 
protein. Slides created from pts’ samples underwent automated immunofluorescent 
staining and AR-V7+ CTCs were enumerated. MiRNAs have been evaluated at the same 
time point. 
Results. Since Sep 2016, 31 patients have been enrolled. We compared CTC counts 
between standard assay and the integrated assay and found no statistical differences in 
the mean total CTC number ± SD (Wilcoxon Signed Rank test, p= 0.313).   
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Sixteen out of 28 evaluable patients (57%) had 1 or more CTCs at baseline, 9 pts (32%) 
had more than 5 CTCs/7.5 ml, and 4 pts (14.3%) were AR-V7+ before any exposure to 
abiraterone or enzalutamide. 
After a median follow-up time of 8.1 months, 6 patients have progressed and 4 have died. 
No association has been found between CTCs ≥ 5/7.5 mL and survival. The presence of at 
least one AR-V7+ CTC at baseline did not correlate with PSA response, but had a weak 
association with shorter PFS (log-rank test, p = 0.055) and a statistically significant impact 
(p = 0.02) on OS.  
MiRNA failed in this analysis to correlate with survival outcome. 
Conclusion. We developed a new integrated assay for detecting AR-V7+ CTCs, based on 
an automated platform that permits serial sampling with low inter- and intra-test variability. 
The clinical utility of this test in anticipating the resistance to abiraterone or enzalutamide is 
under study. 
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1. INTRODUCTION. 
Prostate cancer (PCa) is the most prevalent malignancy in Western countries, and 
the second leading cause of cancer-related mortality in men [1,2]. Nine out of ten patients 
are diagnosed with localized disease and managed by primary curative treatment (either 
surgery or radiotherapy) or active surveillance. In European countries, during the last 
decade, the 5-year relative survival rate for PCa steadily increased up to 84% [3]. This 
result is undoubtedly due to the extensive use of PSA screening, despite the other side of 
the coin being over-diagnosis and over-treatments [4]. However, the risk of developing 
metastatic disease during long-term follow-up is not negligible, and can range cumulatively 
from 26% to 38% after radical prostatectomy or other curative approaches. Moreover, 
around 4% of the patients are initially diagnosed with metastatic disease [5] and morbidity 
and mortality by PCa are mainly caused by metastases. Therefore, there is an unmet need 
to improve our ability to stratify patients according their risk and to predict the treatment 
outcome.  
The aim of treatment for metastatic prostate cancer (mPCa) is to halt, or at least to 
slow down, the disease progression: medical castration, using a luteinizing-releasing 
hormone (LHRH) agonist or antagonist, or bilateral orchiectomy is the most common first-
line therapy (androgen deprivation therapy, ADT) [6]. At first disease progression, intense 
androgen blockade, by adding bicalutamide, could be considered [7], even if this second 
hormonal manipulation has never demonstrated to impact on survival. 
Recently, data presented at American Society of Medical Oncology (ASCO) Annual 
Meeting in 2015 showed a significant benefit in overall survival (OS) from adding six 
courses of docetaxel to ADT at diagnosis in patients with mPCa at presentation and high 
volume disease [8]. Based also on the subsequent results of STAMPEDE and FETUG 
AFU15 trials [9, 10] the addition of docetaxel to ADT should now be considered standard 
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care for men with metastatic hormone-sensitive prostate cancer who are newly diagnosed 
with metastatic disease [11]. 
More recently, data from 2017 ASCO Annual Meeting indicated a survival gain from 
the addition of abiraterone acetate to ADT in mPCa at first presentation [12, 13]. 
When disease progresses to first line therapy, it becomes a metastatic castration-
resistant prostate cancer (mCRPC). In a hormone-sensitive disease, multiple mechanisms 
have been described in the attempt to explain the development of CRPC. Despite castrate 
level of androgens, AR signalling still remains the key of the development of resistance. 
Constitutively active AR splicing variants, AR gene amplification and/or overexpression, 
AR gene mutation, and an unclear role for AR cofactors [14] have led to the knowledge 
that CRPC is not androgen independent, and continues to rely on androgen signalling [15]. 
In the castration-resistant setting, treatment strategies have traditionally consisted 
of hormonal therapy, chemotherapy, bisphosphonates, radioisotopes, and best supportive 
care (BSC), with several new treatment options approved in the last few years. 
Chemotherapy may lead to PSA level decrease and symptomatic improvements: 
docetaxel is the standard first line chemotherapy with a medial OS gain of 2.4 months 
compared to mitoxantrone [16]; cabazitaxel, a different drug belonging to the taxane 
family, has been approved after docetaxel failure since it improves OS [17]; mitoxantrone 
continue to be a further chemotherapy option although with unknown impact on survival.  
Furthermore, several anti-hormonal drugs have recently emerged for the treatment 
of mCRPC base on the new knowledge on AR signalling. Abiraterone is a cytochrome 
P450 17A1 (CYP17A1) inhibitor that impairs androgen-receptor signalling by depleting 
adrenal and intratumoral androgens [18]. It has been approved for second or further line 
therapy after docetaxel [19] in mCPRC patients, and in the chemo-naïve setting [20], 
thanks to the relevant survival gain demonstrated in large randomized trials conducted 
against placebo. 
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Enzalutamide is an inhibitor of androgen-receptor signalling that exerts its activity by 
binding avidly to the ligand-binding domain of the androgen receptor, competing with and 
displacing the natural ligands of this receptor (testosterone and dihydrotestosterone) while 
also inhibiting translocation of the androgen receptor into the nucleus and impairing 
transcriptional activation of androgen-responsive target genes. Randomized trials provided 
solid data of OS improvement, therefore it has been firstly approved for second or further 
line of therapy after docetaxel [21], and later also for first line treatment in chemo- naïve 
patients [22]. 
More recently, the radiometabolic agent radium 223 has been introduced for the 
treatment of mCRPC [23] with bone only metastatic disease. 
Since different drugs can be used in first or second line therapy and some of them 
can be used in both settings, the best treatment sequence is still debated and no definitive 
data are available. The treatment choice should be done by an oncologist trained in PCa’s 
management and, possibly, by a Prostate Unit, and should take into account the presence 
of visceral vs bone disease, symptoms related to the disease, the need for disease 
shrinkage, comorbidities, and finally patients’ preference. 
Although enzalutamide and abiraterone represent breakthroughs in the treatment of 
mCRPC, approximately 20 to 40% of patients show immediate resistance to these agents 
[19, 21]. Among patients who initially respond, virtually all acquire secondary resistance. 
One of the plausible explanation for the resistance could be the presence of androgen 
receptor splice variants (AR-V) [24, 25]. These alternatively variants encode a truncated 
AR protein that lacks the C-terminal ligand-binding domain but retains the transactivating 
N-terminal domain [26]. The truncated proteins are unable to bind ligand, but they are 
constitutively active as transcription factors capable of promoting activation of target 
genes, such as KLK3 (PSA), KLK2 (HK2), TMPRSS2 and NKX3-1. Although supported by 
preclinical studies, the clinical significance of AR-V in patients receiving enzalutamide or 
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abiraterone has been long unknown until the results of the first study by Antonarakis and 
colleagues [27] which showed that the presence of AR-V7 transcript in circulating mCRPC 
cells may be associated with resistance to enzalutamide or abiraterone. 
Further studies showed that levels of AR-V correlate with PCa progression [28], and 
expression of AR-V7 increases markedly upon androgen deprivation [29]. These findings 
suggest that AR-Vs may contribute to clinical progression of PCa. 
Besides, subsequent studies indicated that AR-Vs not only supports the broad 
androgen/AR transcriptional program, but may also uniquely transcriptionally activate 
alternative targets genes associated the regulation of the cell [30]. AR-V7 is the most 
clinically relevant variant, because it is the most frequently observed and the most 
abundant AR-V in clinical specimens, and the only one that can be detected reproducibly 
at both the mRNA and protein levels. From the first Antonarakis’s report [27] we learnt that 
the prevalence of AR-V7 was higher in enzalutamide-treated men who had previously 
received abiraterone and vice versa; AR-V7 prevalence was lowest in men who did not 
receive either agent. In addition, authors reported that all men with baseline detection of 
AR-V7 remained positive during the therapy, while 14% of patients with negative AR-V7 
status at baseline converted to AR-V7-positive during treatment. The baseline presence of 
AR-V7 is thought to be a negative predictive factor for treatment with enzalutamide or 
abiraterone. 
However, more data on biomarkers in patients with mCRPC are needed. An assay 
measuring a tumour marker must be evaluated in order to demonstrate its analytic and 
clinical validity, and at the end its clinical utility (the results of the assay should lead to a 
clinical decision that evidently improves patient outcome) [31]. Thus, a marker must 
encompass several levels of evidence in the attempt to demonstrate its clinical utility, with 
the final aim to improve patients’ outcome, in terms of OS, disease-free survival and 
quality of life, and obtain a more cost-efficient application of effective therapies. The Tumor 
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Marker Utility Grading System (TMUGS) establishes an agenda for evaluating the clinical 
utility of tumour markers, and describes five levels of evidence as “categories that define 
the quality of data available on which the utility score is based”. These levels range from 
the weak level V evidence, derived from case reports and clinical examples, to the 
strongest level I evidence, “the definitive demonstration of clinical utility, obtained by a 
single, high-powered, prospective, randomized, controlled trial or from a meta-analysis or 
overview of multiple, well-designed studies”, passing through intermediate degrees of 
evidence in levels II–IV.  
Many studies have illustrated the potential of liquid biopsy as tumour marker. The 
concept of liquid biopsy has gradually evolved reaching nowadays a wider field of 
application from the initial idea of “leukemic phase of solid tumours” [32]. Circulating 
tumour cells (CTCs) were described for the first time in 1869 by Ashworth, who 
documented the presence of cells “identical with those of the cancer itself” in the blood of a 
metastatic cancer patient. In 2001, Pachmann et al. combined laser scanning cytometry 
with immunomagnetic bead enrichment to detect and quantify rare tumour cells in 
peripheral blood and bone marrow [33]. A few years later, the association of CTC number 
and patient outcome was demonstrated in metastatic breast cancer using the CellSearch® 
platform (Janssen Diagnostics, LLC, Raritan, NJ, USA), a semi-automated system that 
immunomagnetically enriches epithelial cell adhesion molecule (EpCAM)-positive CTCs 
and enumerates them as (EpCAM+) CK+ DAPI+ CD45− cells [34].  
Despite the great number of technologies developed to enrich, isolate and 
characterize these metastatic seeds of neoplasm, only the CellSearch® technology has 
demonstrated the clinical validity of CTC quantification (level I evidence) as a prognostic 
factor for metastatic breast cancer, by a pooled analysis of individual patient data 
published in 2014 [35].  
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The CellSearch® CTC Kit has been cleared by the Food and Drug Administration 
(FDA) for detection and enumeration of CTCs of epithelial origin in whole blood of 
metastatic colon, prostate and breast cancers. Specifically, for mCRPC, the EpCAM+ CTC 
number strongly correlates to prognosis: a cut-off value of 5 CTC/7.5 mL of peripheral 
blood has been validated, and patients whose CTC number is above this cut-off are at 
high risk of progression and shorter OS when treated with chemotherapy or abiraterone 
[36-38]. Since 2015, the CTC level has been included in the international guidelines for its 
prognostic value in metastatic breast cancer and, later, in prostate cancer. However, its 
predictive value and clinical utility are still under discussion.  
More in detail, current limits to an extensive use of CTC assays in the clinical setting 
include: the lack of a consensus about the features that are necessary and sufficient to 
define an event as CTC; the poor ability to track tumour cells undergoing epithelial-to-
mesenchymal-transition (EMT), responsible for the loss of epithelial markers in favour of 
the mesenchymal ones; the sensitivity of the techniques with a limit of detection of CTCs in 
no more than 50% of metastatic patients; the lack of a comprehensive genomic 
characterization of the circulating compartment together with a reliable assessment of its 
heterogeneity [39].  
More recently, the identification of AR‑V7 as a potential marker of resistance for 
treatment with abiraterone or enzalutamide has increased the interest in CTC as a tool for 
promoting personalized treatment [40], since AR-V7 has been isolated from CTCs.  
MicroRNAs (miRNAs) are endogenous, short (18-25 nucleotides) single-stranded 
noncoding RNAs found in eukaryotic cells, synthesized and processed in the nucleus (pre-
miRNA) before being exported to the cytoplasm (mature miRNA). Depending on the 
degree of complementarity with the 3′ untranslated region (UTR), miRNAs can degrade or 
block the translation of their target mRNAs, and thus play a significant regulatory role in 
various biological processes, such as gene expression, cell proliferation, apoptosis, viral 
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defence, metabolism, hematopoietic differentiation and tumorigenesis [41-43]. Some of 
them have been identified as associated to the presence and aggressiveness of prostate 
cancer [44-47]: miR141, a member of miR-200 family, is abnormal in a wide range of 
common human cancers and it is over-expressed in prostate carcinoma, raising a 
controversial issue about the role of miR141 in cancer progression [48, 49]. As far as for 
miR141, significantly higher expression levels of miR-375 were depicted in PCa patients 
with higher Gleason score and more advanced pathological stage, as well as with regional 
lymph nodes metastases [50]. Some miRNAs are also predictive factors: for instance, 
overexpression of mir-181a in PCa cells contributes to their resistance to docetaxel and 
cabazitaxel [51]. 
Apart from and association with a more aggressive clinical and biological behaviour, 
the role of miR141 and miR375 in prostate cancer remains largely unknown. A recent work 
performed at our Institution has demonstrated that miR-106a/miR-103b and miR-
106a/miR-223 in patients treated with curative intent may correlate with the development 
of metastases [52]. 
Co-primary aims of the present study are to investigate AR-V7 with a new 
integrated assay and to study role of miRNAs in mCRPC patients treated with abiraterone 
or enzalutamide, and to study the relationship between AR-V7 expression, CTCs, and 
miRNAs with PFS or OS. 
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2. MATERIALS AND METHODS. 
Population. We designed an exploratory, prospective trial, enrolling patients with mCRPC 
who are candidate to receive abiraterone or enzalutamide with or without previous 
treatment with docetaxel. Key inclusion criteria included life expectancy greater than 6 
months; disease progression after therapy with LHRH agonist or antagonist, with or 
without anti-androgen drugs (bicalutamide, flutamide); previous treatment with docetaxel 
administered for either castration-sensitive or resistant CRPC was allowed but not 
mandatory; absence of clinical contraindications to abiraterone or enzalutamide, adequate 
compliance to study procedures. All patients had to sign an informed consent form. All 
anti-neoplastic drugs have been administered according to current label authorisation in 
Italy and administered until progression, or unacceptable toxicity. No change of treatment 
or dose was recommended based on the results of this study. The choice between 
abiraterone or enzalutamide was made according to patients’ comorbidities and potential 
contraindications to steroids, which should be given along with abiraterone but not with 
enzalutamide. Adverse events have been treated according to the best knowledge 
available at the time of their appearance. Disease progression has been defined as 
radiological (according to PCWG3 or RECIST criteria), or clinical (deterioration of general 
conditions). 
Detection of miRNA. The expression of miRNAs has been evaluated by quantitative PCR 
of miRNAs selected from total RNA extracted. miR141 and miR375 have been tested. At 
each time point, 5 ml of blood anticoagulated with EDTA was collected from patients and 
then processed at our laboratory at Istituto Oncologico Veneto. Plasma was separated on 
Ficoll Plus (GE Healthcare) in 13 ml tubes (5 ml of blood on 4ml of Ficoll) and centrifuged 
at 581g (1800 rpm) for 30 minutes. Then, supernatant was removed (plasma 
approximatively 2 ml) 1ml above PBMC without mixing or touching it and then plasma was 
collected in 1.5ml eppendorf tubes. Subsequently, plasma was spinned at 2.500g for 15 
13 
minutes at room temperature and divided in 2ml eppendorf tubes. The tubes were stored 
at -80°C before RNA extraction. RNA extraction was conducted with NucleoSpin miRNA 
plasma kit (Macherey-Nagel©) according to manufacturer instruction, then extracted RNA 
was diluted in 30 µl of DNAse/RNAse free H2O. 5 µl of total RNA were used for first-strand 
cDNA synthesis in 15 µl reaction volume using the TaqMan miRNA Reverse Transcription 
kit (Applied Biosystems©) and miRNA specific stem-loop primers. TaqMan specific miRNA 
assay and Light Cycler 480 Probe Master (Roche©) was used according to the 
manufacturers’ protocol. All samples were run at least in duplicate including no-RT and no-
template negative controls in a total volume of 20 µl reaction. A total of 45 amplification 
cycles were run. Absolute quantification was carried out on LightCycler 480 II (Roche©) 
with the automatic settings using the second derivative maximum method. This method 
permits to identify the threshold cycle (Ct) of a sample as the point where the slope of the 
sample’s fluorescence curve exhibits the highest flexus (Software Version, handbook, 
Roche), thus minimizing biases due to the operator. All amplification curves were carefully 
controlled for artifacts, and inadequate samples were discarded from the analysis. Only 
Ct<40 values were considered. Mean values from duplicate/triplicate runs were calculated 
for each miRNA. Values of the miRNA obtained have been normalized with normal 
expressed miRNA 130b in order to analyse the data [52]. 
Detection of CTCs and AR-V7. The CTCs have been assessed with CellSearch™ System 
(Veridex©), which is the first automated platform for the capture, enrichment, identification 
and enumeration of CTCs in the peripheral blood [34]. We used this system according to 
manufacturer’s instruction. An event was classified as a CTC when its morphological 
features were consistent with those of a tumour cell, and it exhibited the phenotype 
EpCAM+, CK+, DAPI+ and CD45- [53]. Quantitative results were expressed as the total 
number of CTCs per 7.5 ml of blood. In order to develop a new CS assay for the detection 
of AR-V7 in CTCs, we also integrated the standard CS assay with a monoclonal antibody 
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(mAb) that recognizes the variant 7 of the Androgen Receptor (AR-V7 EPR15656 abcam 
final concentration 0.87mg/ml), as previously performed for developing other CS integrated 
assays by our research group [53, 54]: slides created from mCRPC patient samples 
underwent automated immunofluorescent staining for AR-V7. 
Timepoints. miRNA, CTC, AR-V7 have been evaluated on day 1 and after 28 days, 
thereafter at 3 months, 6 months, 9 months during treatment and at disease progression or 
at 12 months without progression, whichever comes first. 
Statistical consideration. Progression was measured from the start of treatment until 
radiological or clinical progression (defined by PCWG3 criteria) or death; overall survival 
was calculated from start of treatment to death. Survival of patients lost to follow-up was 
checked with the national registry. PFS and OS were estimated using the the Kaplan-
Meier method, and subgroups with different values of CTCs, AR-V7+ CTCs, and miRNAs 
at baseline and during treatment were compared with log-rank test. Fisher’s exact Chi-
squared test was used to evaluate the predictive accuracy of miRNAs levels, PSA 
response and CTC and AR-V7 positivity with progression and survival. 
Ethical consideration. The study has been approved by local Ethics Committee at Istituto 
Oncologico Veneto, before any patient was enrolled. 
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3. RESULTS. 
Population. Between September 2016 and August 2017, thirty-two patients have been 
prospectively enrolled onto this study at Istituto Oncologico Veneto. One patient refused to 
continue the study immediately after the signature of the consent form due to personal 
logistic reasons. Considering the cohort of the thirty-one male patients who have at least a 
baseline assessment, median age was 75.2 years (range from 57.7 to 89.6 years). All the 
patients had a histologic diagnosis of PCa: 14 of them (45%) underwent radical 
prostatectomy, 14 (45%) patients underwent radical radiotherapy, 17 (55%) received only 
prostatic biopsy on primary tumor. Median Gleason Score was 8 (range from 6 to 10). 
Most of the patients (23, 74%) had bone metastases, 17 patients (55%) had lymph nodes 
disease, and 2 of them (6%) had also local relapse. No patients had visceral disease in 
this cohort. Most of the patients had ECOG performance status 1 (74%), all the others are 
performance status 0 (26%). 
The majority of patients were at first line therapy for mCRPC (26 patients, 84%), while 5 
patients (16%) had already received a standard first line chemotherapy with docetaxel. 
Eight patients (26%) received abiraterone, while the other 26 (74%) received 
enzalutamide, reflecting investigators’ choice.  
At the baseline assessment, mean PSA level was 19.2 ng/ml (range from 0.5 to 1550 
ng/ml). 
Population characteristics are summarized in the following table: 
Patients’ characteristics (n=31) 
Median age (range) 75.2 years (57.7-89.6) 
ECOG Performance Status 
- 0 
- 1 
 
8 (26%) 
23 (74%) 
Previous treatment of primary tumor 
- prostatectomy 
- radiotherapy 
- only biopsy 
 
14 (45%) 
3 (10%) 
14 (45%) 
16 
Site of disease 
- bone metastases 
- lymph node metastases 
- visceral disease 
- local relapse 
 
23 (74%) 
17 (55%) 
none 
2 (6%) 
Previous treatment for mCRPC 
- none 
- docetaxel 
 
26 (84%) 
5 (16%) 
 
Response. Based on serial PSA levels, 20 patients (65%) had a PSA decrease greater 
than 50% within the first assessment at three months after enrolment; 10 patients (32%) 
had no PSA response (3 had PSA progression according to PWCG3 criteria [Scher, JCO 
20016], 7 had stable PSA levels); 1 patient (3%) is still not evaluable. 
On the radiologic side, 8 patients (25%) are not yet evaluable. Out of 23 evaluable patients 
for best response, 6 (26%) had a radiological response according to RECIST criteria, 15 
patients (65%) had stable disease, and 2 patients (9%) had disease progression. 
CTC counts and AR-V7 expression and development of an integrated assay.  
Initially, we enumerated CTCs with the standard CS assay and with our new integrated CS 
assay able to identify AR-V7+ CTCs by means of a new monoclonal antibody (mAb) 
recognizing the variant 7 of the Androgen Receptor. Firstly, we compared the CTC levels 
measured by standard assay and the integrated assay in the firstly enrolled patients. 
Eleven patients were considered. The graph in figure 1 shows the mean total CTC number 
± SD in the standard and integrated assay and we did not find any statistically significant 
difference (Wilcoxon Signed Rank test, p= 0.313). Thus, we can stat that any difference 
obtained using the two different tests could be attributed to chance. Therefore, after the 
first eleven patients, we used only one test to enumerate at the same time both total CTCs 
and AR-V7+ CTCs from peripheral blood sample. 
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Figure 1. Mean total CTC number ± SD in the standard and integrated assay (Wilcoxon Signed Rank test, p= 0.313) 
 
With the integrated CS assay, CTCs expression with the determination of the eventual 
presence of AR-V7+ CTCs has been tested at baseline and in all the following 
assessments for all the patients of the cohort.  
Cells with morphological features consistent with those of a tumour cell, and 
exhibiting the phenotype EpCAM+, CK+, DAPI+ and CD45- were enumerate as CTCs. 
Those cells staining also for AR-V7 were classified as AR-V7+ CTCs. 
For three patients, basal value of CTC was not available due to technical issue. 
Sixteen out of 28 evaluable patients (57%) had CTCs at baseline, of whom 9 (32%) had a 
basal value of CTC higher than 5/7.5 ml which (prognostic cut-off for mCRPC patients). 
Among all these patients, 4 (14.3%) also expressed AR-V7+ CTCs at baseline, before any 
exposure to either abiraterone or enzalutamide. 
miRNA expression. miRNA expression has been tested at the baseline and at all the 
following assessments for the first 15 patients among the study population. miR141 and 
miR375 were expressed at baseline in all the patients. A trend to statistical significance 
has been found in the correlation between prospective changes of these two miRNAs and 
PSA response according to PCWG3 criteria (Fisher’s exact test, p=0.057). Instead, no 
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statistically significant correlation has been found between changes of levels of these two 
miRNAs with radiological response. Data on the value of miR141/130b ratio and 
miR375/130b are shown in figure 2 and 3 respectively. 
 
 
Figure 2. miR141/130b ratio during the study. Linear graphic for each patient (each line represents a patient). 
 
 
 
Figure 3. miR375/130b ratio during the study. Linear graphic for each patient. (each line represents a patient). 
 
 
Survival analyses. After a median follow-up time of 8.1 months, median OS or PFS have 
not been reached: 6 patients (19%) have progressed and 4 (13%) died. 
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 The curves of OS and PFS are shown in figure 4. 
 
Figure 4. OS (a) and PFS (b) for the whole population. 
 
As previously reported [37] we stratified all the patients according to CTC number of 5 or 
more cells. In the evaluable population (n=28), at the time of this analysis 94.7% of 
patients with CTC counts negative or below the cut-off are alive, while 88.9% of patients 
with at least 5 CTCs are alive, this difference being not statistically significant (Kaplan-
Meier, log-rank test, p = 0,453). 
PFS was slightly superior for patients with less than 5 CTC at baseline compared to the 
other group, but again there was not a statistically significant difference (log-rank test, p = 
0,910). 
We also analysed the changes of CTC number and of AR-V7+ CTC number during the 
treatment. As the whole population is numerically small, the differences among groups are 
not great enough to exclude statistically a random sampling variability and the level of 
expression does not vary over the time (Kruskal Wallis On Way analysis of variance on 
ranks, p=0.414 and p=0.562 respectively) (figure 5). 
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Figure 5. Changes of CTC number and of AR-V7+ CTC number during the treatment (Kruskal Wallis On Way analysis of 
variance on ranks, p=0.414 and p=0.562 respectively). 
 
We also stratified the patients according to AR-V7+ CTC number of 1 or more cells. In our 
cohort, we found a weak association between AR-V7+ CTCs in peripheral blood at 
baseline and shorter PFS (log-rank test, p = 0,055) (figure 6) and a statistically significant 
impact on OS (log-rank test, p = 0,02) (figure 7), between the two groups. 
 
 
Figure 6. PFS for AR-V7+ CTC vs AR-V7- patients 
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Figure 7. OS for AR-V7+ CTC vs AR-V7- patients 
 
Representative cases. Some interesting cases have been identified during the analyses. 
During the first year of follow-up, 4 patients died out of 32 enrolled patients and 2 of them 
had more than 5 CTCs at baseline blood draw. 
Three out of 4 deceased patients did not show AR-V7+ CTCs at baseline, and initially 
responded to the treatment, showing important reduction of tumor burden (2 out of 4) and 
persistence of CTC level lower than 5 cells; then one of them showed ARV7+ CTCs at the 
time of progression (data shown in figure 8). 
 
. 
 
 
 
Figure 8. Representative cases for CTCs and AR-V7+ CTCs variation over time (longitudinal graphic) 
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Regarding miRNAs, one patient showed concordant variations over time of PSA, 
miR141/103b ratio and miR375/103b ratio. On the other side, another patient with 
increasing value of such miRNAs achieved a radiological and biochemical response (figure 
9).  
 
 
Figure 9. Representative cases for miRNA variation over time (longitudinal graphic). 
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4. DISCUSSION. 
Thirty-two consecutive patients with mCRPC seen at our institution have been 
prospectively enrolled into an academic clinical trial aiming to assess the prognostic and 
predictive role of AR-V7+ CTCs and the two miR141 and miR375 during treatment with 
either abiraterone or enzalutamide. All of them had bone and/or lymph nodal disease and 
no visceral disease; median age was 75.2 years and a good proportion of them had not 
undergone any treatment on the primary tumor but only biopsy (45%). All patients were 
ECOG performance status 0 or 1. Population characteristics are very close to what has 
been yet reported in the registrative trials of abiraterone and enzalutamide. In the 
PREVAIL study [20] median age of the enzalutamide subgroup was 72 years and Gleason 
score was the same of our study; in the same way, there were no patients with ECOG 
performance status greater than 1. In the abiraterone pre-chemotherapy trial [19] the 
population has the same general characteristics.  
Since one of the main aims of the study was to investigate AR-V7 with a new 
integrated assay able to enumerate total CTCs and AR-V7+ CTCs at the same time, firstly 
we have validated the test. In a previously reporter paper, Antonarakis et al. [27] identified 
AR-V7 through mRNA expression. The analyses were performed using the 
ProstateCancerDetect kit with multiplexed reverse-transcription polymerase-chain-reaction 
(qRT-PCR) primers to detect the presence of CTCs, and custom primers designed to 
detect the full-length-AR (AR-FL) and AR-V7. The relative AR-V7 transcript abundance 
was determined by calculating the ratio of AR-V7 to AR-FL. In our study, to quantify the 
fraction of AR-V7+ CTCs, we integrated the standard CS assay with a monoclonal 
antibody that recognizes the variant 7 of the Androgen Receptor, analysed with the fourth 
filter of the CellSearch System. Results were expressed as the total number of CTCs and 
AR-V7+ CTCs per 7.5 mL of peripheral blood. For the first enrolled patients, we have 
enumerated the CTCs with both the assays. Since we did not find any statistically 
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significant difference between the two groups, any difference obtained using the two 
different tests could be attributed to chance; therefore, we proceeded to use the integrated 
assay to enumerate CTCs and AR-V7+ CTCs in serial samples with lower inter- and intra-
test variability than other reported tests detecting AR-V7 mRNA. 
Regarding CTCs, it is already proven that CTC is a validate biomarker for prostate 
cancer [37]: a value equal or greater 5 CTC/7.5 ml is a negative prognostic factor. At the 
time of this writing, baseline CTC values show only a trend to significance in our cohort but 
this may be attributed to the low number of events and needs to be re-assessed with 
longer follow-up. We will try going to confirm the prognostic role of the basal value of CTC 
with a longer period of follow-up and a greater number of event, hopefully having reached 
median value of OS and PFS.  
It is widely known that AR-V7 is associated with resistance to enzalutamide and 
abiraterone [25]. AR-V7 has been found to be significantly upregulated during PCa 
progression; moreover, expression of AR-V7 in primary prostate tumours has been 
demonstrated predictable for survival outcome after radical prostatectomy [55]. In a 
previous study, Hornberg et al. [56] the AR-V7 transcripts were demonstrated to increase 
in mCRPC compared with metastatic hormone-sensitive PCa and to be associated with a 
poor prognosis. Moreover, a recently published analysis confirms that patients positive for 
AR-V7+ CTCs before starting abiraterone or enzalutamide experience more PSA 
increases, shorter time on therapy and PFS, and also shorter OS compared to patients 
without AR-V7 expression [57]. In our cohort, AR-V7 was present in 14.3% of patients at 
baseline. This is in line with the expectation, since AR-V7 expression before treatment with 
enzalutamide or abiraterone ranged from 9% to 15% in other published reports [58].  
Analysing the subgroup of patients with at least one AR-V7+ CTCs we found a 
statistically significant impact on OS and a weak association with PFS, but the small 
numbers do not allow us to compare patients according to relevant clinical and 
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pathological prognostic factors and to carry out a multivariate analysis. A longer period of 
observation and a higher number of events are necessary to confirm if the difference is 
statistically robust. A larger, and possibly multicenter study is warranted in order to confirm 
the clinical utility of this test with the final aim of incorporating it in the clinical practice of 
mCRPC management. 
It has already been demonstrated that miR-141 and miR-375 are associate with a 
more aggressive behaviour of PCa. No data are available on predictive or prognostic role 
of miRNAs in mCRPC treated with hormonal agents. We hypothesized a possible role of 
the levels of these miRNAs in predicting shorted PFS and OS, but data collected up to 
now in our cohort are conflicting and do not allow us to draw any conclusion. In fact, no 
correlation has been found between baseline level of miR-375 and miR-141 expression 
and time to radiological or biochemical response, as well as with survival. Most likely, more 
preclinical data are needed to assess the role of miRNAs in developing of hormone 
resistance and/or alternative miRNAs should be studied. 
Major limitation of the present study is the small number of patients and the short 
period of observation allowing only a quite small number of events to happen. In the 
published data, median PFS and OS with abiraterone or enzalutamide are around 18 and 
35 months, respectively [22, 59].  
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5. FUTURE PERSPECTIVE. 
As already discussed, the main limitation of the present study is the short follow-up: 
we therefore need to follow patients for a longer period of time in order to collect a greater 
number of events and assess the correlation between CTC number, AR-V7+ CTC number 
and control of disease and survival. 
Moreover, we have planned to investigate the pathological samples of the primary 
tumours in the attempt to demonstrate with immunohistochemistry and/or molecular 
biology the presence of AR-V7 in the primary prostate tumor of the 4 patients with baseline 
expression of AR-V7. 
Finally, we are going to perform droplet digital PCR in the AR-V7+ CTCs sample 
collected in our study to have molecular identification of the splicing variant of androgen 
receptor. 
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6. CONCLUSION. 
We developed a new integrated assay for detecting ARv7+ CTCs by combining the 
standard CS assay (IVD) with a specific mAb detecting the splicing variant 7 of the 
Androgen Receptor. In comparison with previously reported assays, our test is based on 
an automated platform that permitted serial sampling with low inter- and intra-test 
variability, characteristics that are mandatory to plan clinical prospective studies and to 
introduce companion diagnostics in the clinical routine.  
We found that the new assay is a feasible tool for detecting AR-V7+ CTCs and to 
study their dynamic changes under the pressure of hormonal drugs.  
The clinical utility of this test in anticipating the resistance to enzalutamide and 
abiraterone is under study. 
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